Three poster presentations at ASGCT 2023 will highlight the development of Aspect’s bioprinted liver tissue platform
Vancouver, BC, Canada - May 15, 2023 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, will present three posters highlighting the development of its bioprinted liver tissue platform at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, held May 16-20, 2023, in Los Angeles, CA and virtually.
Aspect is leveraging its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design, to create bioprinted tissue therapeutics for currently incurable diseases such as genetic and acquired liver diseases. These tissue therapeutics are rationally engineered to be biologically functional, immune-protective, and suitable for surgical implantation.
“We believe that our full-stack tissue therapeutic platform holds immense potential to radically redefine the treatment of acquired and genetic liver diseases,” said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. “We have taken great strides in advancing our liver tissue therapeutic platform and look forward to sharing new preclinical data at ASGCT 2023.”
Poster Presentation Details:
Comparative Analysis of SubQ vs IP Implanted Hepatocyte-Containing Bioprinted Tissues
- Date/Time: Wednesday May 17, 2023, 12:00 PM
- Session: Wednesday Poster Session
- Poster Board Number: 652
3D Bioprinted Liver Tissues Rescue a Murine Model of CCl4- Induced Acute Liver Failure
- Date/Time: Friday May 19, 2023, 12:00 PM
- Session: Friday Poster Session
- Poster Board Number: 1450
Bioprinted Liver Tissues as a Cell Therapy for Phenylketonuria
- Date/Time: Friday May 19, 2023, 12:00 PM
- Session: Friday Poster Session
- Poster Board Number: 1654
All abstracts are available on the ASGCT website here.
About Aspect Biosystems
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases. Learn more at www.aspectbiosystems.com.
Contact
Natalie Korenic
Aspect Biosystems
media@aspectbiosystems.com